Total Voting Rights and Capital
In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GlaxoSmithKline plc (the 'Company') hereby notifies the market of the following:
The Company's issued share capital as at 29 April 2022 consisted of 5,388,880,497 shares of 25 pence each ('Ordinary Shares'), of which 304,905,950 Ordinary Shares were held in Treasury.
Therefore, the total number of voting rights in the Company is 5,083,974,547. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
V A Whyte
3 May 2022